The WOC Skin Health Weekly®, a weekly e-news publication packed with career empowerment resources including the latest clinical, industry, and product news, clinical education, market research, and of course, the most recently posted jobs requiring expertise in the prevention and treatment of skin breakdown and wound care. Over 20,000 clinicians now receive the WOC Skin Health Weekly.
Receive your own complimentary subscription to the WOC Skin Health Weekly®
For years, medical investigators have tried and failed to develop vaccines for a type of staph bacteria associated with the deadly superbug MRSA. But a new study by Cedars-Sinai investigators shows how staph cells evade the body's immune system, offering a clearer picture of how a successful vaccine would work. Staph frequently causes skin infections but occasionally can lead to deadly conditions such as sepsis, pneumonia and bloodstream infections, particularly in hospitalized patients whose immune systems could be weakened by illness. Read More
Scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed a new gel patch prototype that could speed up the healing of a skin wound while minimising the formation of scars. The team unveiled the patch today as a proof-of-concept. When fully developed, this healing patch could be a boon for diabetic patients, who suffer from hard-to-heal skin lesions and for patients undergoing surgery. The new patch is unlike other single-purpose patches in the market, which either reduce the scarring or improve healing, but not both. Read More
Our veins have valves that carry deoxygenated blood from all over the body toward the heart. In case of veinous insufficiency, valves of the leg veins get damaged, which makes for backward flow of blood in the legs. The rise of blood in the legs increases the blood pressure, and thus nutrients and gases are not absorbed by the tissues. Cells in the legs start dying, leading to wound formation. The following things can increase a patient's chances of getting these ulcers. Read More
Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported interim results in its Phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Three adult non-collagenous (NC)1+ patients have been dosed with a single intradermal injection session of FCX-007 in the margins of and across targeted wounds, as well as in separate intact skin sites. Five wounds were treated on the three subjects, ranging in size from 4.4cm2 to 13.1cm2. Read More